Business
PAOG RespRx CBD Pharmaceutical Respiratory Treatment In The Spotlight
PAOG RespRx CBD Pharmaceutical Respiratory Treatment In The Spotlight.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG RespRx CBD Pharmaceutical Respiratory Treatment In The Spotlight\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG RespRx CBD Pharmaceutical Respiratory Treatment In The Spotlight\nPR Newswire\nSANDUSKY, Ohio, Oct. 14, 2021\n\n\n\nSANDUSKY, Ohio, Oct. 14, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced encountering a flurry of outside interest of late into the company's CBD pharmaceutical respiratory treatment research.\nLast year, the company acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960).  The ongoing research targets the treatment of respiratory disorders in support of a pharmaceutical being developed by PAOG under the name RespRx.\nPAOG has engaged Veristat as a CRO to prepare an IND for the FDA.\nOf late, CBD is becoming more universally recognized for is respiratory health benefits.  For example:\nCOPD: Can CBD Help?\nThe Latest Information On CBD Covid Implications\nIn conjunction with PAOG's ongoing IND initiative for RespRx, and PAOG's connection with U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING,\" PAOG is now receiving unsolicited contacts expressing interests ranging from investment and partnership to acquisition.\nPAOG is not altering its plans at this stage in reaction to the recent interest.  The company will continue developing its pharmaceutical and nutraceutical treatments.\nPAOG expects to realize its first CBD nutraceutical product sales beginning imminently in Q4, 2021.\nThe company confirms shipping its first CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (USOTC: USMJ).\nPAOG plans to announce specifics about its first CBD nutraceutical product in an upcoming formal product launch announcement once the distributor is set up to begin sales and distribution.\nPAOG expects revenue to grow rapidly following its first CBD nutraceutical product launch as the company has follow on products lined up to follow the first product addin...